Abstract
Epithelial ovarian cancer is the third most frequent fatal cancer of women in Australia and is one of the leading causes of female cancer deaths in the United States, Northern Europe, Canada and Israel (1,2). There are no identified preventable causes and no reliable means for early diagnosis so that improved survival must lie with the optimal management of patients. While there have undoubtedly been major advances in radiotherapy and chemotherapy over the last 3 decades, the available data suggest that these developments have not improved survival rates for the group of patients with epithelial ovarian cancer. This may be attributed, in part, to a lack of understanding of the multiplicity of prognostic variables that contribute to the outcome of patients with ovarian cancer and perhaps inappropriate selection between treatment options (3).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Australian & New Zealand journal of obstetrics & gynaecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
